Status:
COMPLETED
Salivary Alpha Amylase as a Biomarker of Transdermal Vagus Nerve Stimulation
Lead Sponsor:
Arkansas Tech University
Conditions:
No Condition Salivary Alpha Amylase
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The proposed project tests the hypothesis that salivary alpha amylase concentration is a reliable biomarker of the effect of transdermal vagus nerve stimulation (tVNS) in humans.
Detailed Description
The study examines the capacity of tVNS to alter the concentrations of salivary alpha amylase. Changes in salivary alpha amylase concentrations reflect alteration of CNS structures anatomically linked...
Eligibility Criteria
Inclusion
- Healthy individuals
Exclusion
- NA
Key Trial Info
Start Date :
March 31 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 8 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03854539
Start Date
March 31 2018
End Date
June 8 2020
Last Update
June 18 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Arkansas Tech University
Russellville, Arkansas, United States, 72801